Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01236508|
Recruitment Status : Terminated (difficulties recruiting this population for study population)
First Posted : November 8, 2010
Last Update Posted : April 24, 2017
|Condition or disease||Intervention/treatment||Phase|
|TIA Stroke Carotid Artery Stenosis||Radiation: PET/CT imaging with F-18 fluorodeoxyglucose||Phase 4|
- To investigate the relationship of carotid inflammation, as measured by FDG positron emission tomography (PET) to standardized uptake value in atherosclerotic plaque, with the number of covert brain infarcts.
- To investigate the relationship of FDG PET standardized uptake value with the relative volume of white matter hyperintensity.
- To correlate vascular inflammation in the entire aorta and aortoiliac vessels to carotid inflammation and cerebral infarcts and white matter disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||October 27, 2016|
|Actual Study Completion Date :||October 27, 2016|
Experimental: Nuclear imaging
PET/CT imaging with F-18 fluorodeoxyglucose
Radiation: PET/CT imaging with F-18 fluorodeoxyglucose
Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
- Plaque Inflammation [ Time Frame: 30 days ]The extent to which plaque inflammation, as measured by the extent of FDG uptake, contributes to the number of covert infarcts and the magnitude of white matter hyperintensity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01236508
|The Ottawa Hospital, Civic Campus|
|Ottawa, Ontario, Canada, K1Y 4E9|
|Principal Investigator:||Terrence Ruddy, MD||The Ottawa Hospital|